|
|
|
Volumn 1, Issue 1, 2001, Pages 4-5
|
|
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
QUINAZOLINE DERIVATIVE;
ARTICLE;
CLINICAL TRIAL;
DRUG ANTAGONISM;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
PHASE 2 CLINICAL TRIAL;
CARCINOMA, NON-SMALL-CELL LUNG;
HUMANS;
LUNG NEOPLASMS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 0035372454
PISSN: 14737140
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|